Revenue potential like all biotech start-up (plus they got over the big hurdle of regulatory approval but still waiting on the biggest on FDA). There currently isn't a better technology in the market that you keep alluding to, that company hasn't even done or started any clinical trial (last I heard they were still trying to find funding).
Ann: Quarterly Update and Appendix 4C, page-60
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)